DK2019683T4 - Indgivelse af vækstfaktorer til behandling af CNS-lidelser - Google Patents

Indgivelse af vækstfaktorer til behandling af CNS-lidelser Download PDF

Info

Publication number
DK2019683T4
DK2019683T4 DK07761286.9T DK07761286T DK2019683T4 DK 2019683 T4 DK2019683 T4 DK 2019683T4 DK 07761286 T DK07761286 T DK 07761286T DK 2019683 T4 DK2019683 T4 DK 2019683T4
Authority
DK
Denmark
Prior art keywords
administration
treatment
growth factors
cns disorders
cns
Prior art date
Application number
DK07761286.9T
Other languages
English (en)
Other versions
DK2019683T3 (da
Inventor
Krystof S Bankiewicz
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38656355&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2019683(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ California filed Critical Univ California
Publication of DK2019683T3 publication Critical patent/DK2019683T3/da
Application granted granted Critical
Publication of DK2019683T4 publication Critical patent/DK2019683T4/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/242—Gold; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/244—Lanthanides; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0083—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the administration regime
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
    • A61K49/0447—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is a halogenated organic compound
    • A61K49/0461—Dispersions, colloids, emulsions or suspensions
    • A61K49/0466—Liposomes, lipoprotein vesicles, e.g. HDL or LDL lipoproteins, phospholipidic or polymeric micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1806—Suspensions, emulsions, colloids, dispersions
    • A61K49/1812—Suspensions, emulsions, colloids, dispersions liposomes, polymersomes, e.g. immunoliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1217—Dispersions, suspensions, colloids, emulsions, e.g. perfluorinated emulsion, sols
    • A61K51/1234—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Psychology (AREA)
  • Dispersion Chemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Radiology & Medical Imaging (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Psychiatry (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
DK07761286.9T 2006-04-25 2007-04-25 Indgivelse af vækstfaktorer til behandling af CNS-lidelser DK2019683T4 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79501206P 2006-04-25 2006-04-25
PCT/US2007/067423 WO2007127803A2 (en) 2006-04-25 2007-04-25 Administration of growth factors for the treatment of cns disorders

Publications (2)

Publication Number Publication Date
DK2019683T3 DK2019683T3 (da) 2017-03-20
DK2019683T4 true DK2019683T4 (da) 2022-08-29

Family

ID=38656355

Family Applications (1)

Application Number Title Priority Date Filing Date
DK07761286.9T DK2019683T4 (da) 2006-04-25 2007-04-25 Indgivelse af vækstfaktorer til behandling af CNS-lidelser

Country Status (12)

Country Link
US (5) US7922999B2 (da)
EP (1) EP2019683B2 (da)
JP (2) JP6105187B2 (da)
AU (1) AU2007244826B2 (da)
BR (1) BRPI0710800A2 (da)
DK (1) DK2019683T4 (da)
ES (1) ES2618787T5 (da)
HU (1) HUE030903T2 (da)
PL (1) PL2019683T5 (da)
PT (1) PT2019683T (da)
SI (1) SI2019683T2 (da)
WO (1) WO2007127803A2 (da)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7442370B2 (en) 2001-02-01 2008-10-28 Biogen Idec Ma Inc. Polymer conjugates of mutated neublastin
US7276580B2 (en) 2001-03-12 2007-10-02 Biogen Idec Ma Inc. Neurotrophic factors
WO2004094592A2 (en) 2003-04-18 2004-11-04 Biogen Idec Ma Inc. Polymer-conjugated glycosylated neublastin
CA2577690C (en) * 2004-08-19 2013-08-06 Biogen Idec Ma Inc. Refolding transforming growth factor beta family proteins
DK1786454T3 (da) * 2004-08-19 2010-09-06 Biogen Idec Inc Neublastinvarianter
MX2007003850A (es) 2004-10-05 2007-11-21 Genzyme Corp Canula escalonada.
EP1928557B1 (en) 2005-08-23 2018-06-06 The Regents of The University of California Reflux resistant cannula and system for chronic delivery of therapeutic agents using convection-enhanced delivery
TWI501774B (zh) * 2006-02-27 2015-10-01 Biogen Idec Inc 神經性病症之治療
EP1872790A1 (en) * 2006-06-26 2008-01-02 DeveloGen Aktiengesellschaft New formulation for increasing bioavailability of neurturin
EP2142205B1 (en) 2007-05-01 2014-04-02 Biogen Idec MA Inc. Neublastin peptides for use in increasing vascularisation in tissue with impaired blood flow
US20090130017A1 (en) * 2007-11-19 2009-05-21 Searete Llc Targeted short-lived drug delivery
WO2009111649A2 (en) * 2008-03-05 2009-09-11 Regenerative Research Foundation Methods and compositions for delivery of exogenous factors to nervous system sites
EP4502152A3 (en) 2009-10-06 2025-04-30 Regeneron Pharmaceuticals, Inc. Genetically modified mice and engraftment
PL2558154T3 (pl) 2010-04-16 2020-11-30 Clearpoint Neuro, Inc. Systemy chirurgiczne MRI zawierające kaniule chirurgiczne kompatybilne z MRI do transferu substancji do i/lub od pacjenta
US9045751B2 (en) 2010-04-28 2015-06-02 The Regents Of The University Of California Modified small activating RNA molecules and methods of use
CA2802896C (en) 2010-07-01 2021-05-11 Regenerative Research Foundation Methods for culturing undifferentiated cells using sustained release compositions
EP2646468B1 (en) 2010-12-01 2018-07-25 AlderBio Holdings LLC Anti-ngf compositions and use thereof
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
GB201101167D0 (en) * 2011-01-22 2011-03-09 Renishaw Plc Convection enhanced delivery apparatus and method
SG10202008003VA (en) 2011-02-15 2020-10-29 Regeneron Pharma Humanized m-csf mice
EP2839013B1 (en) 2012-04-18 2020-08-26 The Board of Trustees of the Leland Stanford Junior University Non-disruptive gene targeting
AU2013266968B2 (en) 2012-05-25 2017-06-29 Emmanuelle CHARPENTIER Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
FI2892330T3 (fi) 2012-09-07 2023-03-25 Univ Yale Geneettisesti muokattuja hiiriä ja menetelmiä niiden käyttämiseksi
MX377561B (es) 2012-11-05 2025-03-10 Regeneron Pharma Animales no humanos genéticamente modificados y métodos de uso de los mismos.
WO2014179760A1 (en) 2013-05-03 2014-11-06 The Regents Of The University Of California Cyclic di-nucleotide induction of type i interferon
WO2014202833A1 (en) * 2013-06-18 2014-12-24 University Of Helsinki Treatment of neuronal injuries
US9891296B2 (en) 2013-09-13 2018-02-13 MRI Interventions, Inc. Intrabody fluid transfer devices, systems and methods
SG11201707615YA (en) 2013-09-19 2017-10-30 Univ Leland Stanford Junior Methods and compositions for producing hepatocyte-like cells
US9932607B2 (en) 2013-11-15 2018-04-03 The Board Of Trustees Of The Leland Stanford Junior University Site-specific integration of transgenes into human cells
CA2930877A1 (en) 2013-11-18 2015-05-21 Crispr Therapeutics Ag Crispr-cas system materials and methods
EP3835419A1 (en) 2013-12-12 2021-06-16 The Regents of The University of California Methods and compositions for modifying a single stranded target nucleic acid
BR112016019940A2 (pt) 2014-03-21 2017-10-24 Univ Leland Stanford Junior edição de genoma sem nucleases
LT3137497T (lt) 2014-05-02 2021-07-26 Genzyme Corporation Aav vektoriai, skirti tinklainės ir cns genų terapijai
MX2016014995A (es) 2014-05-19 2017-03-31 Regeneron Pharma Animales no humanos geneticamente modificados que expresan eritropoyetina de humano.
RU2716991C2 (ru) 2014-11-05 2020-03-17 Вояджер Терапьютикс, Инк. Полинуклеотиды aadc для лечения болезни паркинсона
US10377818B2 (en) 2015-01-30 2019-08-13 The Board Of Trustees Of The Leland Stanford Junior University Method of treating glioma
CN107530447A (zh) 2015-02-10 2018-01-02 建新公司 病毒颗粒至纹状体和皮质的增强递送
JP6836999B2 (ja) 2015-03-24 2021-03-03 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアＴｈｅ Ｒｅｇｅｎｔｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃａｌｉｆｏｒｎｉａ アデノ随伴ウイルス変異体及びその使用方法
ES2950399T3 (es) 2015-04-13 2023-10-09 Regeneron Pharma Ratones humanizados Sirpa-IL15 insertados y métodos de uso de los mismos
JP6853257B2 (ja) 2015-09-23 2021-03-31 サンガモ セラピューティクス， インコーポレイテッド Ｈｔｔリプレッサー及びその使用
US20190048340A1 (en) 2015-09-24 2019-02-14 Crispr Therapeutics Ag Novel family of rna-programmable endonucleases and their uses in genome editing and other applications
WO2017142698A1 (en) 2016-02-17 2017-08-24 MRI Interventions, Inc. Intrabody surgical fluid transfer assemblies with adjustable exposed cannula to needle tip length, related systems and methods
US20200291369A1 (en) 2016-03-11 2020-09-17 Erasmus University Medical Center Rotterdam Improved CRISPR-Cas9 Genome Editing Tool
WO2017155407A1 (en) 2016-03-11 2017-09-14 Wageningen Universiteit Improved crispr-cpf1 genome editing tool
WO2018044933A1 (en) 2016-08-30 2018-03-08 The Regents Of The University Of California Methods for biomedical targeting and delivery and devices and systems for practicing the same
US11332713B2 (en) 2016-11-16 2022-05-17 KSQ Therapeutics, Inc. Gene-regulating compositions and methods for improved immunotherapy
IL266862B2 (en) 2016-12-01 2024-01-01 Sangamo Therapeutics Inc Tau modulators and methods and preparations for their administration
AU2017378427A1 (en) 2016-12-14 2019-06-20 Ligandal, Inc. Methods and compositions for nucleic acid and protein payload delivery
US10889800B2 (en) * 2017-05-25 2021-01-12 New York Stem Cell Foundation, Inc. Method and composition for generating basal forebrain cholinergic neurons (BFCNS)
JOP20190269A1 (ar) 2017-06-15 2019-11-20 Voyager Therapeutics Inc بولي نوكليوتيدات aadc لعلاج مرض باركنسون
CA3070087A1 (en) 2017-07-17 2019-01-24 Voyager Therapeutics, Inc. Trajectory array guide system
EP3707155A2 (en) 2017-11-09 2020-09-16 Vertex Pharmaceuticals Incorporated Crispr/cas systems for treatment of dmd
JP2021506251A (ja) 2017-12-14 2021-02-22 クリスパー セラピューティクス アーゲー 新規ｒｎａプログラム可能エンドヌクレアーゼ系、ならびにゲノム編集および他の適用におけるその使用
WO2019123414A1 (en) 2017-12-22 2019-06-27 Straximm Llp Engineered viruses expressing cyclic gmp-amp synthase
CN112040986A (zh) 2018-03-15 2020-12-04 Ksq治疗公司 用于改进的免疫疗法的基因调控组合物和方法
US20190284553A1 (en) 2018-03-15 2019-09-19 KSQ Therapeutics, Inc. Gene-regulating compositions and methods for improved immunotherapy
MA52074A (fr) 2018-03-19 2021-01-27 Bayer Healthcare Llc Nouveaux systèmes d'endonucléase à arn programmable et leurs utilisations
US11253237B2 (en) 2018-05-09 2022-02-22 Clearpoint Neuro, Inc. MRI compatible intrabody fluid transfer systems and related devices and methods
US11022664B2 (en) 2018-05-09 2021-06-01 Clearpoint Neuro, Inc. MRI compatible intrabody fluid transfer systems and related devices and methods
KR20210019996A (ko) 2018-05-15 2021-02-23 보이저 테라퓨틱스, 인크. 파킨슨병의 치료를 위한 조성물 및 방법
EP3793543A1 (en) * 2018-05-18 2021-03-24 Neurotrope Bioscience, Inc. Methods and compositions for treatment of alzheimer's disease
CA3109141A1 (en) 2018-08-10 2020-02-13 New York Univeristy Use of mannose 6 phosphate and modifications thereof for memory enhancement and reducing memory impairment
MX2021001595A (es) 2018-08-10 2021-06-08 Univ New York Uso de ligandos agonistas del receptor igf-2 para el tratamiento del sindrome de angelman y autismo.
EP3856762A1 (en) 2018-09-28 2021-08-04 Voyager Therapeutics, Inc. Frataxin expression constructs having engineered promoters and methods of use thereof
WO2020072677A1 (en) 2018-10-02 2020-04-09 Sangamo Therapeutics, Inc. Methods and compositions for modulation of tau proteins
CN113710799B (zh) 2018-11-28 2024-11-12 克里斯珀医疗股份公司 用于在LNP中使用的编码CAS9的优化mRNA
CN109381488A (zh) * 2018-12-22 2019-02-26 包桂荣 癫痫病的外用药剂及制备方法
WO2020152607A1 (en) 2019-01-22 2020-07-30 St. Jude Children's Research Hospital Modulation of lc3-associated endocytosis pathway and genetically modified non-human animals as a model of neuroinflammation and neurodegeneration
WO2020163856A1 (en) 2019-02-10 2020-08-13 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Modified mitochondrion and methods of use thereof
EP3934641A4 (en) 2019-03-07 2022-12-21 Ilera Therapeutics LLC FORMULATIONS FOR THE TREATMENT OF SYMPTOMS ACCOMPLISHED WITH AUTISM
WO2020209959A1 (en) 2019-03-08 2020-10-15 Crispr Therapeutics Ag Nucleobase-editing fusion protein systems, compositions, and uses thereof
SG11202109741VA (en) 2019-03-12 2021-10-28 Crispr Therapeutics Ag Novel high fidelity rna-programmable endonuclease systems and uses thereof
TW202521561A (zh) 2019-04-23 2025-06-01 美商聖加莫治療股份有限公司 染色體9開放讀框72基因表現之調節子及其用途
CN110192859B (zh) * 2019-05-05 2020-05-19 兰月 一种磁共振测量人脑类淋巴通路清除效率的方法
US20210047649A1 (en) 2019-05-08 2021-02-18 Vertex Pharmaceuticals Incorporated Crispr/cas all-in-two vector systems for treatment of dmd
US11684750B2 (en) 2019-10-08 2023-06-27 Clearpoint Neuro, Inc. Extension tube assembly and related medical fluid transfer systems and methods
WO2022018638A1 (en) 2020-07-21 2022-01-27 Crispr Therapeutics Ag Genome-editing compositions and methods to modulate faah for treatment of neurological disorders
AU2022290382A1 (en) 2021-06-11 2023-11-23 Bayer Aktiengesellschaft Type v rna programmable endonuclease systems
EP4101928A1 (en) 2021-06-11 2022-12-14 Bayer AG Type v rna programmable endonuclease systems
EP4144841A1 (en) 2021-09-07 2023-03-08 Bayer AG Novel small rna programmable endonuclease systems with impoved pam specificity and uses thereof
EP4453191A1 (en) 2021-12-23 2024-10-30 Bayer Aktiengesellschaft Novel small type v rna programmable endonuclease systems
CN119403922A (zh) 2022-06-10 2025-02-07 拜耳公司 新的小型v型rna可编程内切核酸酶系统
WO2024178397A2 (en) 2023-02-24 2024-08-29 Elevatebio Technologies, Inc. Modified immune effector cells and methods of use
EP4688851A1 (en) 2023-03-27 2026-02-11 LAVA Therapeutics N.V. Nectin-4 binding agents and methods of use
AU2024277678A1 (en) 2023-05-25 2025-11-27 Dispatch Biotherapeutics, Inc. Synthetic cancer antigens as targets for treating cancers
CN121729237A (zh) 2023-06-30 2026-03-24 武田药品工业株式会社 Htt阻遏物及其用途
WO2025012118A2 (en) 2023-07-07 2025-01-16 LAVA Therapeutics N.V. 5t4 binding agents and methods of use
WO2025171388A1 (en) 2024-02-09 2025-08-14 Dispatch Biotherapeutics, Inc. Engineered cancer antigens with modified domains and related methods and uses
WO2025171383A2 (en) 2024-02-09 2025-08-14 Dispatch Biotherapeutics, Inc. Engineered cancer antigens and related methods and uses
WO2026085108A2 (en) 2024-10-14 2026-04-23 Immusoft Corporation B cell compositions and methods of use

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US37410A (en) 1863-01-13 Improvement in machines for seaming metal roofing
US5843473A (en) 1989-10-20 1998-12-01 Sequus Pharmaceuticals, Inc. Method of treatment of infected tissues
AU679167B2 (en) 1991-09-20 1997-06-26 Amgen, Inc. Glial derived neurotrophic factor
WO1995005864A1 (en) * 1993-08-27 1995-03-02 Government Of The United States Of America, Represented By The Secretary Of The Department Of Health And Human Services Convection-enhanced drug delivery
FR2717824B1 (fr) 1994-03-25 1996-04-26 Rhone Poulenc Rorer Sa Virus recombinants, préparation et utilisation en thérapie génique.
DE69527194T2 (de) 1994-03-28 2003-02-06 Daiichi Pharmaceutical Co., Ltd. Liposomen enthaltend ein röntgen- oder ultraschallkontrastmittel
ATE386131T1 (de) 1994-04-13 2008-03-15 Univ Rockefeller Aav-vermittelte überbringung von dna in zellen des nervensystems
US5626862A (en) 1994-08-02 1997-05-06 Massachusetts Institute Of Technology Controlled local delivery of chemotherapeutic agents for treating solid tumors
US5733875A (en) * 1994-11-15 1998-03-31 Amgen Inc. Methods of using GDNF as a neuroprotective agent
FR2727867B1 (fr) 1994-12-13 1997-01-31 Rhone Poulenc Rorer Sa Transfert de genes dans les motoneurones medullaires au moyen de vecteurs adenoviraux
US5830857A (en) 1995-07-14 1998-11-03 Amgen Inc. Method of treating epilepsy
US5731284A (en) 1995-09-28 1998-03-24 Amgen Inc. Method for treating Alzheimer's disease using glial line-derived neurotrophic factor (GDNF) protein product
US5741778A (en) 1996-03-19 1998-04-21 Amgen Inc. Method for treating Huntington's disease using glial cell line-derived neurotrophic factor (GDNF) protein product
ES2392246T3 (es) 1996-11-12 2012-12-07 The Regents Of The University Of California Preparación de formulaciones estables de complejos de lípido-ácido nucleico para el suministro eficaz in vivo
US6042579A (en) 1997-04-30 2000-03-28 Medtronic, Inc. Techniques for treating neurodegenerative disorders by infusion of nerve growth factors into the brain
ES2288766T3 (es) * 1997-09-09 2008-01-16 Curis, Inc. Efectos sinergicos de morfogenes op/bmp y factores neurotroficos gdnf/ngf.
CA2301693A1 (en) 1997-09-19 1999-04-01 Klaus Unsicker Cytokines having neurotrophic activity
US6451306B1 (en) 1998-04-15 2002-09-17 The Regents Of The University Of California Methods for therapy of neurodegenerative disease of the brain
US7157435B2 (en) 1998-04-15 2007-01-02 The Regents Of The University Of California Methods for modulation of the effects of aging on the primate brain
US6815431B2 (en) 1998-04-15 2004-11-09 Regents Of The University Of California Methods for therapy of neurodegenerative disease of the brain
WO1999061066A2 (en) 1998-05-27 1999-12-02 Avigen, Inc. Convection-enhanced delivery of aav vectors
US7018628B1 (en) 1998-07-24 2006-03-28 Aventis Pharma S.A. Vectors derived from baculovirus and use for transferring nucleic acids into nerve cells of vertebrates
US6800281B2 (en) 2000-11-09 2004-10-05 Oxford Biomedica (Uk) Limited Lentiviral-mediated growth factor gene therapy for neurodegenerative diseases
CA2327208A1 (en) * 2000-11-30 2002-05-30 The Government Of The United States Of America Methods of increasing distribution of therapeutic agents
US7182944B2 (en) 2001-04-25 2007-02-27 The United States Of America As Represented By The Department Of Health And Human Services Methods of increasing distribution of nucleic acids
IL162838A0 (en) 2002-01-04 2005-11-20 Univ Rockefeller Compositions and methods for prevention and treatment peptide-of amyloid- related disorders
ES2581781T3 (es) * 2002-09-24 2016-09-07 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Método por imágenes para administración mejorada por convección de agentes terapéuticos
US8946151B2 (en) 2003-02-24 2015-02-03 Northern Bristol N.H.S. Trust Frenchay Hospital Method of treating Parkinson's disease in humans by convection-enhanced infusion of glial cell-line derived neurotrophic factor to the putamen
US20040209810A1 (en) 2003-02-24 2004-10-21 Gill Steven S. Method of treating Parkinson's disease in humans by intraputaminal infusion of glial cell-line derived neurotrophic factor
US20050112065A1 (en) 2003-07-09 2005-05-26 Drummond Daryl C. Remote detection of substance delivery to cells
US20060258576A1 (en) * 2003-09-05 2006-11-16 Licentia, Ltd Gdnf-related neuropeptides
EP1750673B1 (en) 2004-05-17 2009-12-02 Tekmira Pharmaceuticals Corporation Liposomal formulations comprising dihydrosphingomyelin and methods of use thereof
GB2414934A (en) * 2004-06-11 2005-12-14 Gill Steven Streatfield Treatment of Parkinson's disease with GDNF

Also Published As

Publication number Publication date
JP2014224140A (ja) 2014-12-04
BRPI0710800A2 (pt) 2012-01-17
WO2007127803A2 (en) 2007-11-08
US20140017297A1 (en) 2014-01-16
ES2618787T3 (es) 2017-06-22
US9724387B2 (en) 2017-08-08
US20070254842A1 (en) 2007-11-01
US7922999B2 (en) 2011-04-12
US8409548B2 (en) 2013-04-02
DK2019683T3 (da) 2017-03-20
SI2019683T1 (sl) 2017-04-26
US9050299B2 (en) 2015-06-09
US20180140672A1 (en) 2018-05-24
EP2019683B1 (en) 2016-12-14
ES2618787T5 (es) 2022-10-21
JP2009535359A (ja) 2009-10-01
PL2019683T5 (pl) 2022-12-05
PT2019683T (pt) 2017-03-17
US20120009245A1 (en) 2012-01-12
EP2019683A4 (en) 2010-08-11
AU2007244826B2 (en) 2013-04-11
WO2007127803A3 (en) 2008-10-23
JP6105187B2 (ja) 2017-03-29
EP2019683B2 (en) 2022-08-03
EP2019683A2 (en) 2009-02-04
JP6190336B2 (ja) 2017-08-30
AU2007244826A1 (en) 2007-11-08
SI2019683T2 (sl) 2022-10-28
US20150313962A1 (en) 2015-11-05
HUE030903T2 (en) 2017-06-28
PL2019683T3 (pl) 2017-06-30

Similar Documents

Publication Publication Date Title
DK2019683T4 (da) Indgivelse af vækstfaktorer til behandling af CNS-lidelser
DK3456707T3 (da) 4-(p-quinonyl)-2-hydroxybutanamidderivater til behandling af mitokondriesygdomme
DK1874781T3 (da) Dihydrothienopyrimidiner til behandling af inflammatoriske sygdomme
DK2474321T3 (da) Sammensætninger til behandling af collagenmedierede sygdomme
DK2504005T3 (da) Anvendelse af 1,3-diphenylprop-2-en-1-on-derivater til behandling af lever-sygdomme
DK2545939T3 (da) Tetrahydrobiopterin til behandling af tilstande associeret med forhøjede phenylalaninniveauer
DK2102169T3 (da) Indazolylamidderivater til behandling af glucocorticoidreceptormedierede forstyrrelser
DK2086944T3 (da) Fremgangsmåde til fremstilling af difluormethylpyrazolylcarboxylater
IL192692A0 (en) Compounds for the treatment of inflammatory disorders
PL3354276T3 (pl) Kompozycje do leczenia zapalenia przewodu pokarmowego
IL192691A0 (en) Hydantoin compounds for the treatment of inflammatory disorders
SMAP200900085A (it) 3-imidazolil-indoli per il trattamento di malattieproliferative
DK2010184T3 (da) Implatanter til behandlingen af dopamin associerede tilstande
DK2207550T3 (da) Tetrahydroquinolinderivater til behandling af post-traumatiske stress-lidelser
DK2285808T3 (da) Spiroindolderivater til behandling af parasitsygdomme
DK2209900T3 (da) Anvendelse af bakterier til fremstillingen af bioenergi
DK2056842T3 (da) Modificeret galactosylceramid til behandling af cancerøse sygdomme
BRPI0820440A2 (pt) Inibidores aldh-2 no tratamento de desordens psiquiátricas
DK2117565T3 (da) Anvendelse af chitosaner til behandlingen af negleinflammatoriske sygdomme
ZA200806455B (en) Use of 2-imidazoles for the treatment of CNS disorders
DK2022504T3 (da) Salve til behandling af hæmorider
DK2285416T3 (da) Konjugat til behandlingen af mesotheliom
DK2109449T3 (da) Lægemiddel til behandling af endometriose
IL192877A0 (en) Use of 2-imidazoles for the treatment of cns disorders
DK1982178T3 (da) Fremgangsmåder til behandling af affektbetonede lidelser